Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in wom
about
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureDose schedule optimization and the pharmacokinetic driver of neutropeniaWomen with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentiaAbnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvCrucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis.Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tu
P2860
Q26751249-A652F4F0-F8AF-4A71-B6D0-445418E2B3E5Q28544635-665637BC-5461-4700-B0C1-3E6DA972A72EQ35599471-1BBE46C9-9456-4CF1-BEFB-BE2EED308ADFQ35743162-1183F565-210F-4C47-B1A9-0A19A22B2D51Q36744405-CA0D6A6A-7020-443F-9E39-E2492894284FQ37335249-ED1CBCB8-5B7A-4441-A7EE-5AB69C51D50BQ38682028-B1EFE4B9-AF88-46E4-BFCB-46F188C2DEFAQ41620122-84F09765-6CC4-4BF0-8C9F-74895865D9A3Q47101783-87898130-81A0-4458-B485-C5647408C49BQ48121626-BF37C600-87DD-48A2-8396-6AEDE67EA4DE
P2860
Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in wom
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effects on quality of life, an ...... in and cyclophosphamide in wom
@ast
Effects on quality of life, an ...... in and cyclophosphamide in wom
@en
type
label
Effects on quality of life, an ...... in and cyclophosphamide in wom
@ast
Effects on quality of life, an ...... in and cyclophosphamide in wom
@en
prefLabel
Effects on quality of life, an ...... in and cyclophosphamide in wom
@ast
Effects on quality of life, an ...... in and cyclophosphamide in wom
@en
P2093
P2860
P356
P1433
P1476
Effects on quality of life, an ...... in and cyclophosphamide in wom
@en
P2093
David J Clarke
David Valerio
Ged Cowley
Gerald W Thorpe
Janice Wiseman
Jeanette Beer
Jennifer M Eremin
Jibril A Jibril
Karin Baria
Leslie G Walker
P2860
P2888
P356
10.1186/1471-2407-11-179
P407
P577
2011-05-18T00:00:00Z
P5875
P6179
1032848100